Integrated BioTherapeutics

About Integrated BioTherapeutics

Integrated BioTherapeutics (IBT) operates as a multi-platform entity focused on the discovery and development of vaccines and immunotherapeutics for emerging infectious diseases. The company was founded in 2007 by Dr. M. Javad Aman, a molecular immunologist with extensive experience in developing treatments for infectious diseases at institutions like the US Army Medical Research Institute of Infectious Diseases (USAMRIID). Dr. Aman's background includes a Ph.D. in molecular immunology from the University of Mainz, Germany, followed by post-doctoral work at the NIH and the University of Virginia, shaping the company's research-intensive approach. The firm was established with initial backing from non-dilutive funding from U.S. governmental agencies, including the National Institute of Allergy and Infectious Diseases (NIAID) and the Department of Defense (DoD), along with seed money from Maryland's TEDCO.

The company's business model is twofold. A significant portion of its operations involves proprietary research and development, creating a pipeline of product candidates for bacterial and viral infections, such as Staphylococcus aureus, Ebola, and Marburg viruses. This R&D is substantially funded through government grants and contracts. Concurrently, IBT operates a contract research organization (CRO) under the name IBT Bioservices, which provides a revenue stream to support its internal research programs. This division serves a broad clientele, from biotech startups to large pharmaceutical companies and academic institutions, offering a suite of preclinical services. In February 2023, the company officially rebranded its CRO arm to IBT Bioservices to emphasize its commitment to these services.

IBT Bioservices offers comprehensive 'one-stop-shop' solutions for biotherapeutic development. Its services encompass both in vitro assays—such as antiviral, antibacterial, and immunoassays—and in vivo services, which include over 15 efficacy models for infectious diseases and immunogenicity studies. The company also markets a catalog of research reagents, including recombinant proteins, antibodies, and virus-like particles, available for international shipment. A key milestone was the successful Phase I clinical trial for STEBVax, a component of its S. aureus vaccine candidate, IBT-V02, which demonstrated the safety of a superantigen toxoid in humans and secured significant follow-on funding from CARB-X.